Journal article
Australian and New Zealand consensus statement on the management of lymphoma, chronic lymphocytic leukaemia and myeloma during the COVID-19 pandemic
P Di Ciaccio, G McCaughan, J Trotman, PJ Ho, CY Cheah, S Gangatharan, J Wight, M Ku, H Quach, R Gasiorowski, MN Polizzotto, HM Prince, S Mulligan, CS Tam, G Gregory, G Hapgood, A Spencer, M Dickinson, M Latimer, A Johnston Show all
Internal Medicine Journal | Published : 2020
DOI: 10.1111/imj.14859
Abstract
The COVID-19 pandemic poses a unique challenge to the care of patients with haematological malignancies. Viral pneumonia is known to cause disproportionately severe disease in patients with cancer, and patients with lymphoma, myeloma and chronic lymphocytic leukaemia are likely to be at particular risk of severe disease related to COVID-19. This statement has been developed by consensus among authors from Australia and New Zealand. We aim to provide supportive guidance to clinicians making individual patient decisions during the COVID-19 pandemic, in particular during periods that access to healthcare resources may be limited. General recommendations include those to minimise patient exposur..
View full abstractGrants
Funding Acknowledgements
The Haematology Society of Australia and New Zealand (HSANZ) supports this document with recognition of the need for individual patient decision-making based on data available at that time.